-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Disseminated -X- _ O
or -X- _ O
fatal -X- _ O
Zika -X- _ O
virus -X- _ O
( -X- _ O
ZIKV -X- _ O
) -X- _ O
infections -X- _ O
were -X- _ O
reported -X- _ O
in -X- _ O
immunosuppressed -X- _ O
patients. -X- _ O
Existing -X- _ O
interferon-signaling -X- _ O
/ -X- _ O
receptor-deficient -X- _ O
mouse -X- _ O
models -X- _ O
may -X- _ O
not -X- _ O
be -X- _ O
suitable -X- _ O
for -X- _ O
evaluating -X- _ O
treatment -X- _ O
effects -X- _ O
of -X- _ O
recombinant -X- _ B-Intervention
interferons. -X- _ I-Intervention
METHODS -X- _ O
: -X- _ O
We -X- _ O
developed -X- _ O
a -X- _ O
novel -X- _ O
mouse -X- _ O
model -X- _ O
for -X- _ O
ZIKV -X- _ O
infection -X- _ O
by -X- _ O
immunosuppressing -X- _ O
BALB -X- _ O
/ -X- _ O
c -X- _ O
mice -X- _ O
with -X- _ O
dexamethasone. -X- _ O
RESULTS -X- _ O
: -X- _ O
Dexamethasone-immunosuppressed -X- _ B-Patient
male -X- _ I-Patient
mice -X- _ I-Patient
( -X- _ I-Patient
6–8 -X- _ I-Patient
weeks -X- _ I-Patient
) -X- _ I-Patient
developed -X- _ O
disseminated -X- _ B-Outcome
infection -X- _ I-Outcome
as -X- _ I-Outcome
evidenced -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
detection -X- _ I-Outcome
of -X- _ I-Outcome
ZIKV-NS1 -X- _ I-Outcome
protein -X- _ I-Outcome
expression -X- _ I-Outcome
and -X- _ I-Outcome
high -X- _ I-Outcome
viral -X- _ I-Outcome
loads -X- _ I-Outcome
in -X- _ I-Outcome
multiple -X- _ I-Outcome
organs. -X- _ I-Outcome
They -X- _ O
had -X- _ O
≥ -X- _ B-Outcome
10 -X- _ I-Outcome
% -X- _ I-Outcome
weight -X- _ I-Outcome
loss -X- _ I-Outcome
and -X- _ I-Outcome
high -X- _ I-Outcome
clinical -X- _ I-Outcome
scores -X- _ I-Outcome
soon -X- _ I-Outcome
after -X- _ I-Outcome
dexamethasone -X- _ I-Outcome
withdrawal -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
dpi -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ O
which -X- _ O
warranted -X- _ O
euthanasia -X- _ O
at -X- _ O
12 -X- _ O
dpi. -X- _ O
Viral -X- _ B-Outcome
loads -X- _ I-Outcome
in -X- _ I-Outcome
blood -X- _ I-Outcome
and -X- _ I-Outcome
most -X- _ I-Outcome
tissues -X- _ I-Outcome
at -X- _ I-Outcome
5 -X- _ I-Outcome
dpi -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
than -X- _ I-Outcome
those -X- _ I-Outcome
at -X- _ I-Outcome
12 -X- _ I-Outcome
dpi -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0.05 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Histological -X- _ O
examination -X- _ O
revealed -X- _ O
prominent -X- _ O
inflammatory -X- _ B-Outcome
infiltrates -X- _ I-Outcome
in -X- _ I-Outcome
multiple -X- _ I-Outcome
organs -X- _ I-Outcome
, -X- _ O
and -X- _ O
CD45 -X- _ B-Outcome
+ -X- _ I-Outcome
and -X- _ I-Outcome
CD8 -X- _ I-Outcome
+ -X- _ I-Outcome
inflammatory -X- _ I-Outcome
cells -X- _ I-Outcome
were -X- _ I-Outcome
seen -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
testis. -X- _ I-Outcome
These -X- _ O
findings -X- _ O
suggested -X- _ O
that -X- _ O
clinical -X- _ O
deterioration -X- _ O
occurred -X- _ O
during -X- _ O
viral -X- _ O
clearance -X- _ O
by -X- _ O
host -X- _ O
immune -X- _ O
response. -X- _ O
Type -X- _ O
I -X- _ O
interferon -X- _ O
treatments -X- _ O
improved -X- _ O
clinical -X- _ O
outcome -X- _ O
of -X- _ O
mice -X- _ O
( -X- _ O
100 -X- _ O
% -X- _ O
vs -X- _ O
0 -X- _ O
% -X- _ O
survival -X- _ O
) -X- _ O
. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
Besides -X- _ O
virus -X- _ O
dissemination -X- _ O
, -X- _ O
inflammation -X- _ O
of -X- _ O
various -X- _ O
tissues -X- _ O
, -X- _ O
especially -X- _ O
orchitis -X- _ O
, -X- _ O
may -X- _ O
be -X- _ O
potential -X- _ O
complications -X- _ O
of -X- _ O
ZIKV -X- _ O
infection -X- _ O
with -X- _ O
significant -X- _ O
implications -X- _ O
on -X- _ O
disease -X- _ O
transmission -X- _ O
and -X- _ O
male -X- _ O
fertility. -X- _ O
Interferon -X- _ O
treatment -X- _ O
should -X- _ O
be -X- _ O
considered -X- _ O
in -X- _ O
patients -X- _ O
at -X- _ O
high -X- _ O
risks -X- _ O
for -X- _ O
ZIKV-associated -X- _ O
complications -X- _ O
when -X- _ O
the -X- _ O
potential -X- _ O
benefits -X- _ O
outweigh -X- _ O
the -X- _ O
side -X- _ O
effects -X- _ O
of -X- _ O
treatment -X- _ O
. -X- _ O

